CareDx

CareDx

Noninvasive transplant diagnostics and patient monitoring

Overview

CareDx provides noninvasive tests and digital tools to support people who receive organ transplants. It offers kidney transplant services, HLA typing for organ matching, and digital platforms to manage transplant care from pre-transplant diagnostics to post-transplant monitoring. It also collaborates with biopharma companies to speed clinical development through its pharma services. The products work by using noninvasive tests to monitor transplant health and by providing software that helps doctors, patients, and caregivers track appointments, results, and treatment plans. Unlike many competitors, CareDx combines testing, data management, and patient support in one integrated system and works with pharma partners, focusing on the full transplant journey rather than just a single piece. The goal is to improve transplant outcomes and patient experiences by making testing and care easier, more accurate, and more coordinated.

About CareDx

Simplify's Rating
Why CareDx is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

Biotechnology

Healthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Brisbane, California

Founded

2000

Get referred to CareDx

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CareDx reported Q1 2026 revenue of $117.7 million, up 39% year-over-year, with testing services revenue growing 48%.
  • The $160 million upfront acquisition of Naveris extends CareDx into precision oncology with NavDx, a Medicare-reimbursed liquid biopsy for HPV-driven cancers.
  • Naveris generated $34 million in 2025 revenue with projected 30-40% annual growth, addressing a $4.5 billion total available market.

What critics are saying

  • Naveris integration will consume management attention during CareDx's critical scale-up phase of transplant testing and digital solutions, with high probability in 12-18 months.
  • The $160 million upfront cash outlay plus potential $100 million milestones reduces financial flexibility if oncology growth underperforms over the next 12-24 months.
  • Medicare coverage risk for NavDx threatens revenue as Naveris depends entirely on reimbursement for HPV-driven cancer MRD surveillance adoption.

What makes CareDx unique

  • CareDx is the leading provider of genomics-based information for transplant patients through non-invasive molecular testing.
  • The company uniquely combines AlloMap gene expression profiling with AlloSure donor-derived cell-free DNA testing for comprehensive transplant health monitoring.
  • CareDx serves over 200 solid organ transplant programs in the US and performed over one million molecular tests for organ rejection monitoring.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$152.8M

Below

Industry Average

Funded Over

8 Rounds

Notable Investors:
Post IPO Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Debt Funding Comparison
Coming Soon

Benefits

Health Insurance

Gym Membership

401(k) Company Match

Employee Stock Purchase Plan

Commuter Benefits

Paid Vacation

Stock Price

Growth & Insights

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%

Recently Posted Jobs

Sign up to get curated job recommendations

CareDx is Hiring for 18 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →